Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLibianto, Renata-
dc.contributor.authorEkinci, Elif I-
dc.identifier.citationCritical care clinics 2019; 35(2): 315-328-
dc.description.abstractThe Renaissance of glucose-lowering therapies has arrived with multiple agents that lower blood glucose and demonstrate cardiovascular and renal benefits in people with type 2 diabetes. This article summarizes these new classes of therapies, including the sodium glucose co-transporter-2 inhibitors, glucagon-like peptide-1 agonists, and dipeptidyl peptidase-4 inhibitors. Their cardiovascular safety profile, effects on glycemic, weight, and renal outcomes are discussed. As more options become available to treat type 2 diabetes, clinicians need to be aware of the advantages of each class of medications, beyond their glycemic lowering effects. The safety profiles are summarized in this article.-
dc.subjectDPP-4 inhibitors-
dc.subjectGLP-1 agonists-
dc.subjectNew treatment-
dc.subjectSGLT-2 inhibitors-
dc.titleNew Agents for the Treatment of Type 2 Diabetes.-
dc.typeJournal Article-
dc.identifier.journaltitleCritical care clinics-
dc.identifier.affiliationDepartment of Endocrinology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.

Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.